Loading…
Cabaletta Bio, Inc. is projected to rise to $2.72 by 2027, a +1% move from its current price of $2.68. CABA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.60 | $2.68 | $2.76 | +0.02% |
| Aug 4 | $2.57 | $2.68 | $2.79 | +0.03% |
| Aug 5 | $2.55 | $2.68 | $2.82 | +0.05% |
| Aug 6 | $2.53 | $2.68 | $2.84 | +0.06% |
| Aug 7 | $2.51 | $2.68 | $2.86 | +0.08% |
| Aug 8 | $2.50 | $2.68 | $2.88 | +0.09% |
| Aug 9 | $2.48 | $2.68 | $2.90 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.48 | $2.68 | $2.90 | +0.11% |
| Week 2 | $2.41 | $2.69 | $3.00 | +0.21% |
| Week 3 | $2.35 | $2.69 | $3.07 | +0.32% |
| Week 4 | $2.31 | $2.69 | $3.14 | +0.42% |
| Week 5 | $2.27 | $2.69 | $3.20 | +0.53% |
| Week 6 | $2.23 | $2.70 | $3.26 | +0.64% |
| Week 7 | $2.20 | $2.70 | $3.31 | +0.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cabaletta Bio, Inc. (CABA) operates in the healthcare sector as a clinical-stage biotechnology company focused on discovering and developing engineered T cell therapies for autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for a broad set of autoimmune and related conditions.
The company also develops DSG3-CAART, a CAAR T cell therapy in Phase 1 trials for mucosal pemphigus vulgaris, and MuSK-CAART, an investigational cell therapy in Phase 1 trials for anti-MuSK antibody positive myasthenia gravis. Cabaletta Bio collaborates with institutions and companies including the University of Pennsylvania, Children’s Hospital of Philadelphia, Nanjing IASO Biotherapeutics Co., Ltd, Oxford Biomedica, Autolus Holdings (UK) Limited, and WuXi Advanced Therapies, Inc. The company was incorporated in 2017, is headquartered in Philadelphia, Pennsylvania, and was renamed Cabaletta Bio, Inc.
in August 2018 after previously being Tycho Therapeutics, Inc.
Cabaletta Bio, Inc. is currently priced at $2.67 with a market capitalization of $435.36M and a rank of 3094. The near-term price outlook draws from a published multi-year forecast showing a neutral to bullish path beginning in 2026, with the average price rising from $2.67 in 2026 to higher levels later in the decade and into 2050.
The forecast includes a 2026 average of $2.67 (range $2.04-$3.24; sentiment NEUTRAL), a 2027 average of $2.66 (range $2.07-$3.65; ROI -0.3%; sentiment NEUTRAL), and a 2028 average of $3.21 (range $2.41-$4.60; ROI 20.3%; sentiment BULLISH). By 2030 the average is projected at $3.74 with a 40% ROI, and the path remains bullish through 2040 ($6.12 avg, 129.3% ROI) and 2050 ($12.28 avg, 359.9% ROI). These are estimates and not guarantees, and the forecast shows varying upside and risks across years.
A major floor 15.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.2% away) — a key level to hold.
The nearest ceiling, 19.0% above — a clean break opens room to run.
A major ceiling 54.9% above — clearing it would confirm fresh momentum.
Key CABA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CABA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.69 | Sell | $2.69 | Sell |
| MA 10 | $2.72 | Sell | $2.72 | Sell |
| MA 20 | $2.81 | Sell | $2.80 | Sell |
| MA 50 | $3.08 | Sell | $2.97 | Sell |
| MA 100 | $3.13 | Sell | $3.00 | Sell |
| MA 200 | $2.86 | Sell | $2.92 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.58 | Neutral |
| Stoch RSI (14) | 75.18 | Neutral |
| CCI (20) | -67.68 | Neutral |
| Williams %R (14) | -71.43 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -3.25 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 28.57 | Neutral |
| TRIX (15) | -0.55 | Sell |
| Awesome (5,34) | -0.19 | Sell |
| Ultimate (7,14,28) | 42.09 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 2.67 | Buy |
| ADX (14) | 16.99 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is NEUTRAL. RSI(14) is 40, with the SMA50 at $3.29 and the SMA200 at $2.84. There is a current support level at $2.67 and a resistance level at $3.58, with the stock trading within a 30-day range of $2.14 to $3.34.
These indicators suggest a cautious stance in the near term, with limited upside unless price breaks above the $3.58 level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.04 | $2.68 | $3.32 | 0% | Neutral | |
| $2.15 | $2.72 | $3.63 | +1% | Neutral | |
| $2.59 | $3.37 | $4.69 | +26% | Bullish | |
| $2.96 | $3.94 | $5.65 | +47% | Bullish | |
| $2.85 | $3.88 | $5.72 | +45% | Bullish | |
| $3.00 | $4.17 | $6.28 | +56% | Bullish | |
| $2.99 | $4.24 | $6.51 | +58% | Bullish | |
| $2.88 | $4.16 | $6.51 | +55% | Bullish | |
| $3.20 | $4.70 | $7.48 | +75% | Bullish | |
| $3.45 | $5.15 | $8.31 | +92% | Bullish | |
| $4.33 | $6.94 | $11.96 | +159% | Bullish | |
| $7.81 | $14.23 | $26.96 | +431% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.04 | $2.68 | $3.25 | +0.00% |
| September 2026 | $2.24 | $2.66 | $3.25 | -0.72% |
| October 2026 | $2.28 | $2.72 | $3.35 | +2.12% |
| November 2026 | $2.29 | $2.75 | $3.43 | +1.21% |
| December 2026 | $2.19 | $2.64 | $3.32 | -3.86% |
Click any year to see its month-by-month CABA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cabaletta Bio, Inc.'s 2026 outlook centres on $2.68, within a $2.04 to $3.32 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CABA could reach as high as $3.63, with a base case around $2.72 and support toward $2.15 — roughly +1% from $2.68. A consolidation phase looks the most probable path here.
Expect CABA to range from $2.59 to $4.69 through 2028. The $3.37 average target implies a +26% move from current prices. That is up +24% on the projected 2027 average. Momentum favours further upside here.
The CABA price prediction for 2029 points to an average of $3.94 (low $2.96, high $5.65) — a potential gain of +47% on today's $2.68. Buyers look set to stay in control over this stretch.
In 2030, CABA is projected to trade between $2.85 and $5.72, averaging $3.88 — a potential gain of +45% from today's $2.68. That is -1% versus the projected 2029 average. Momentum favours further upside here.
Cabaletta Bio, Inc.'s 2031 outlook centres on $4.17, within a $3.00 to $6.28 range. That is up +7% on the projected 2030 average. That marks a +56% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CABA could reach as high as $6.51, with a base case around $4.24 and support toward $2.99 — roughly +58% from $2.68. Momentum favours further upside here.
Expect CABA to range from $2.88 to $6.51 through 2033. The $4.16 average target implies a +55% move from current prices. That is -2% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The CABA price prediction for 2034 points to an average of $4.70 (low $3.20, high $7.48) — a potential gain of +75% on today's $2.68. Momentum favours further upside here.
In 2035, CABA is projected to trade between $3.45 and $8.31, averaging $5.15 — a potential gain of +92% from today's $2.68. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cabaletta Bio, Inc.'s 2040 outlook centres on $6.94, within a $4.33 to $11.96 range. That is up +35% on the projected 2035 average. That marks a +159% change versus current levels. Momentum favours further upside here.
By 2050, CABA could reach as high as $26.96, with a base case around $14.23 and support toward $7.81 — roughly +431% from $2.68. Buyers look set to stay in control over this stretch.
Investing $1,000 in CABA today (≈ 373.134328 CABA) could be worth
$5,311.03
+$4,311.03 (+431%) by 2050 · US Dollar
Based on the average projected CABA price of $14.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CABAwould be worth at today's price.
$1,000 invested in CABA on Jul 31, 2025 (≈ 657.894745 CABA) would be worth
$1,763.16
+$763.16 (+76.3%) today · 1.76× · US Dollar
Based on a CABA entry price of $1.52 vs. today's $2.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.69 | $996.28 | -0.4% |
| 1 month ago | $2.99 | $896.32 | -10.4% |
| 3 months ago | $2.94 | $911.56 | -8.8% |
| 6 months ago | $2.5 | $1,072 | +7.2% |
| 1 year ago | $1.52 | $1,763.16 | +76.3% |
| All time (5.0y) ago | $7.14 | $375.35 | -62.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CABA forecast.
Our base-case forecast reaches $5.40 around 2040.
Implied market cap at $5.40: $880.5M
Over the multi-year horizon, the forecast paints a bullish trajectory after a flat start. The 2026 forecast shows an average price of $2.67 with a 0% ROI and NEUTRAL sentiment, followed by a 2027 average of $2.66 with a -0.3% ROI. 2028 turns more positive, with an average of $3.21 and a 20.3% ROI, and 2029 strengthens to an average of $3.75 with a 40.5% ROI.
By 2030 the average reaches $3.74 with a 40% ROI and a BULLISH sentiment. The long-range outlook remains strongly bullish through 2040 (average $6.12, ROI 129.3%) and culminates in 2050 with an average of $12.28 and a ROI of 359.9%. While these are projections, they indicate meaningful upside potential alongside substantial uncertainty and risk over time.
Tap a question to reveal the answer.
2030 — min $2.66, avg $3.74, max $5.70; ROI 40%; sentiment BULLISH.
Forecasts show a path from neutral near term to bullish longer term, with 2028 avg $3.21 (ROI 20.3%), 2029 avg $3.75 (ROI 40.5%), 2030 avg $3.74 (ROI 40%), and 2050 avg $12.28 (ROI 359.9%), though 2026 ROI is 0% and 2027 ROI is -0.3%.
Yes. The forecast includes a 2040 max of $11.12 and a 2050 max of $24.74, so reaching $10 is within the forecast range.
For 2026 the avg price is $2.67 (min $2.04, max $3.24; ROI 0%; sentiment NEUTRAL). The 2027 outlook shows avg $2.66 (min $2.07, max $3.65; ROI -0.3%; sentiment NEUTRAL).
2050 forecasts show an avg of $12.28 with a min of $6.09 and a max of $24.74; ROI 359.9%; sentiment BULLISH.
Cabaletta Bio, Inc. Community Discussion
0Share your Cabaletta Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.